Navigation
banner

Diabetes Summit

2018-04-232018-02-272018-01-19
Register 3 for the price of 2 with the coupon code rcdvb!


PLENARY KEYNOTE SPEAKERS
Domenico Accili

Domenico Accili
Professor of Medicine
Columbia University
Domenico Accili
Professor of Medicine
Columbia University
 
About Speaker:

Dr. Accili serves as the Russell Berrie Foundation Professor of Diabetes, Chief of the Endocrinology Division, and Director of the Diabetes Research Center at Columbia University College of Physicians and Surgeons in New York City, and as an attending physician at New York Presbyterian Hospital.

Highly regarded for transformative findings that have advanced our understanding of the pathogenesis of type 2 diabetes, Dr. Accili has contributed to more than 230 publications.

Dr. Accili’s research has delved into the integrated physiology of insulin action, and mechanisms of pancreatic beta cell failure. He is best known for his work to elucidate mechanisms of hepatic glucose production, enteroendocrine cell differentiation, and beta cell dedifferentiation. Perhaps his most important contributions to date have been in the area of pancreatic beta cell biology, and specifically in the demonstration that beta cell failure, long held to be a consequence of cell death, can result from a dedifferentiation process, whereby beta cells lose the ability to make insulin, revert to a progenitor stage, and convert to other hormone-producing cells. Germane to this discovery is the observation that enteroendocrine cells have the potential to give rise to functional insulin-producing cells in the gut–a property that is being investigated as a therapeutic opportunity for type 1 diabetes.

Dr. Accili’s body of work reflects significant, paradigm-shifting discoveries that hold promise for translating to novel approaches for diabetes prevention and care. He has received numerous awards, including the Banting Medal and the Lilly Award from the American Diabetes Association, the Claude Bernard Medal of the European Association for the Study of Diabetes, the University of Chicago’s Steiner Award, and the Endocrine Society’s Astwood Award. He is an elected member of the Association of American Physicians and the American Society for Clinical Investigation. A member of several editorial boards and advisory panels for academia, government, and industry, his work is supported by the National Institutes of Health and the Russell Berrie Foundation.

Nir Barzilai

Nir Barzilai
Professor, Department of Medicine (Endocrinology); Professor, Department of Genetics
Albert Einstein College of Medicine
Nir Barzilai
Professor, Department of Medicine (Endocrinology); Professor, Department of Genetics
Albert Einstein College of Medicine
 
About Speaker:

Nir Barzilai MD. Director, Institute for Aging Research at the Albert Einstein College of Medicine, PI: Nathan Shock Center of Excellence in the Biology of Aging, PI: Glenn Center for the Biology of Human Aging. Co-Scientific Director of the American Federation for Aging Research Founder and on the Board of CohBar Inc.

Dr. Barzilai is a chaired Professor of Medicine and Genetics and Director of the biggest Center in the world to study the Biology of Aging. He is the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award. He is leading the TAME (Targeting/Taming Aging with Metformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions. He has been featured in major papers, TV program and documentaries and has been Consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, several International Banks, Pepsico, Milkin Institute, The Economist and Wired Magazine.

Brian Bloomquist

Brian Bloomquist
Senior Director, Global External Research and Development
Eli Lilly
Brian Bloomquist
Senior Director, Global External Research and Development
Eli Lilly
 
About Speaker:

Brian has been at Eli Lilly since April 2006 where his role within the Diabetes External Innovation group is to lead the evaluation of external partnering opportunities in diabetes and endocrine disease for technical merit and portfolio fit.  Prior to coming to Lilly, he spent 11 years in the Metabolic Disorders group at Bayer Pharmaceuticals where his laboratory was engaged in obesity drug discovery and he held multiple leadership positions in the management of the Obesity Research portfolio.  Brian completed his post-doctoral studies at The Johns Hopkins University School of Medicine where he studied dopaminergic signaling in the laboratory of Dr. Betty Eipper following his graduate studies at Purdue University where he investigated Drosophila photoreceptor signal transduction under Dr. William Pak and his thesis was awarded the first A.H. Ismail Interdisciplinary Dissertation Award.  Dr. Bloomquist has been a speaker or panelist at multiple conferences including Bio-Europe, GTC Bio, Mass Bio, Ausbiotech, and the Queensland Investment Forum, has been cited in Close Concerns, a leading diabetes and obesity healthcare information company, is an inventor on a number of patents, and is the author of multiple peer-reviewed publications, including an article highlighted on the cover of the journal Cell. 

Andrew Young

Andrew Young
Chief Scientific Officer
Intarcia
Andrew Young
Chief Scientific Officer
Intarcia
 
About Speaker:

Dr. Andrew Young joined Intarcia in September 2015 as Vice President and Chief Scientific Officer. He is most recognized for his role in the discovery and development of several peptide therapeutics for metabolic diseases. He entered industry from academia 29 years ago as the founding physiologist at Amylin Pharmaceuticals, Inc. and pioneered work that illuminated the role of the gut in blood glucose control, co-leading different phases of the development of Symlin® and Byetta®, first-in-class medicines for the treatment of diabetes. He co-founded Satiogen Inc., a San Diego startup related to bile salt stimulation of gut hormone secretion, before joining GlaxoSmithKline in NC as Head of Enteroendocrine Biology. In 2015, with five former GSK colleagues, he co-founded Phoundry Pharmaceuticals, a company dedicated to rendering peptides sufficiently potent for incorporation into innovative delivery systems such as Intarcia’s proprietary mini-pump technology.

Dr. Young received his medical degree as well as graduate science degrees from the University of Auckland School of Medicine, New Zealand, where he also taught physiology. He worked as a Fogarty Fellow for the NIH in Phoenix AZ, studying diabetes in Pima Indians. He worked as a Von Humboldt Fellow at the Max Planck Institute in Bad Nauheim, FRG, studying sensory neurophysiology. He has participated in the development of five approved drugs, authored over 100 original papers and 40 book chapters or books, and is an inventor on over 60 issued US patents.

DISTINGUISHED SPEAKERS
William W. Bachovchin

William Bachovchin
Professor, Department of Biochemistry
Tufts University School of Medicine
William Bachovchin
Professor, Department of Biochemistry
Tufts University School of Medicine
 
About Speaker:

Dr Bachovchin received a BS degree in Biology from Wake Forest University a doctoral degree in Chemistry from The California Institute of Technology, and did postdoctoral work at Harvard Medical School before arriving at Tufts.  Dr. Bachovchin is an author on more than 100 peer reviewed journal articles, and an inventor on more than 40 issued US patents as well as numerous pending applications.  Dr. Bachovchin is a leader in the areas of NMR spectroscopy, enzymes mechanisms and drug design and discovery, especially in areas pertaining to the post proline cleaving family of enzymes.  To date three drugs designed by Dr. Bachovchin have entered human clinical trials and several more are in late stage preclinical testing.  Dr. Bachovchin has founded a several biotechnology companies. These include Point Therapeutic, Arisaph Pharmaceuticals, Bach Biosciences, and IOzyme. He is also Professor of Biochemistry at Tufts University School of Medicine.

Jonathan Behr

Jonathan Behr
Managing Director
JDRF
Jonathan Behr
Managing Director
JDRF
 
About Speaker:

Jon joined the T1D Fund from Partners Healthcare Innovation, where he was a Market Sector Leader and Executive in Residence, driving technology translation from research hospitals affiliated with Harvard Medical School. He previously held senior venture creation roles including Vice President of New Ventures for Enlight Biosciences and Principal at PureTech Ventures (LON:PRTC). Jon has co-founded and supported seven companies (including holding C-level operating, business development and board director positions) and managed alliances with top pharmaceutical companies. He earned his Ph.D. at Massachusetts Institute of Technology as a Howard Hughes fellow and his B.S. from Rice University.

Carl J.Brandt

Carl J. Brandt
Co-founder & Medical Director
Liva Healthcare
Carl J. Brandt
Co-founder & Medical Director
Liva Healthcare
 
About Speaker:

Medical director and co-founder of Liva Healthcare, Dr Carl Brandt is a GP, a research fellow and an entrepreneur. He was one of the co-founders of NetDoctor and has worked on medical solutions to empower patients on the internet for over 15 years. He has founded a number of health services for the internet including NetDoctor, SlankeDoktor.dk, AsktheDoctor24 and most recently Liva Healthcare. He is a research fellow at the University of Southern Denmark and currently works with implementation of online solutions for direct patient communication and lifestyle change. He has undertaken a number of research projects looking at the effectiveness of online digital interventions to help people with their health.

Michael Brehm

Michael Brehm
Associate Professor
University of Massachusetts Medical School
Michael Brehm
Associate Professor
University of Massachusetts Medical School
 
About Speaker:

Dr. Brehm has over 16 years experience in biomedical research with an extensive knowledge of immunological responses to infection agents and to transplantation with non-self tissues. He received his Ph.D. in 1999 from the Department of Microbiology and Immunology at the Pennsylvania State University College of Medicine. During Dr. Brehm’s post-doctoral training at the University of Massachusetts Medical School, he investigated how sequential viral infections impact the ability of a host to generated protective immunity and how viral infections influence transplantation tolerance induced by costimulation blockade. In 2008, he joined the Diabetes Division at the University of Massachusetts Medical School to develop cutting edge mouse models that have been implanted with human cells and tissues to study human biology. Dr. Brehm is currently an Assistant Professor in the Program in Molecular Medicine at the University of Massachusetts Medical School and a member of the UMass Diabetes Center of Excellence. Dr. Brehm’s research program is focused on understanding how human effector T cells are regulated in the context of infectious disease, allo-immunity and auto-immunity. His laboratory is developing “humanized” mice to more effectively study human T cell biology. Dr. Brehm has published over 80 manuscripts and reviews and is supported by funding from the JDRF, NIH and the Helmsley Charitable Trust.

Alan Cherrington

Alan Cherrington
Professor of Molecular Physiology and Biophysics
Vanderbilt University
Alan Cherrington
Professor of Molecular Physiology and Biophysics
Vanderbilt University
 
About Speaker:

Over the past 44 years Dr. Cherrington has carried out important metabolic research using the conscious dog as a model. During that period he, his colleagues and trainees developed an array of unique surgical approaches (trans-hepatic, renal, gut, head, limb cannulation, 3rd ventricle cannulation, liver and renal denervation, carotid body resection, adrenalectomy, pancreatectomy and duodenal bypass) which when combined with clamping (hormone, metabolite) techniques have allowed the performance of experiments not possible anywhere else in the world. Using the dog, which has high translation value to the human, the Cherrington lab can measure whole body metabolism at the same time as organ balance and molecular signaling (using biopsies). In addition they developed a model of T1DM using alloxan, as well as a model of T2DM using diet manipulation. Using this array of techniques and models the Cherrington lab has assessed the way in which hormones, neural mediators, and metabolites interact to control hepatic glucose production (glycogenolysis/gluconeogenesis) and liver glucose uptake (and storage) in the conscious dog. Their work has resulted in almost 300 peer reviewed papers, as well as 87 review articles. It has been recognized with numerous honors including the Lilly and the Banting Awards for research from the ADA and the Rumbough Award for research from the JDRF.

About twelve years ago Dr. Cherrington decided to devote a significant portion of his research effort to helping expedite drug discovery and device development within the pharmaceutical sector. He set up a structure that provided four opportunities for interaction with pharma and bio-tech partners, 1) consulting, 2) direct help with experiments at a given pharma site, 3) contract research within Vanderbilt and lastly 4) contract research with a 3rd party CRO. This menu of services was based on his many years of experience in the field, as well as the ability to carry out unique proof of concept studies utilizing his conscious dog models. He has now worked with a majority of the major pharmaceutical companies (Merck, Novo Nordisk, Eli Lilly, Sanofi, GlaxoSmithKline, Bristol Myers Squib, Hoffman LaRoche, Biocon, Pfizer, Gilead, Boehringer Ingelheim, Boston Scientific, Abbott, Amylin, Takeda, Tanabe) and many small bio-techs (Abvance, Calibr, Fractyl, Galvani, Metavention, NuSirt, Sensulin, Metabasis, Inhale Therapeutics, Silver Lake, Thermalin, Thetis, VTv Therapeutics, Viacyte, Viking, Zafgen, NGM, OSI). The work performed in Cherrington’s lab was often important in shaping the direction of internal programs and in establishing the credibility of a particular approach both within and without the company. Many of the study outcomes have now been published in peer reviewed journals. Of particular note is the work carried out to investigate novel insulin analogues (Biocon – oral insulin; Novo Nordisk – hepatic-preferential insulin; Eli Lilly – hepatopreferential insulin; Thermalin – ultra rapid insulin; Pfizer – inhaled insulin; Merck – glucose responsive insulin). Likewise, work with GLP-1 (Amylin), incretin mimetics (Amylin) and DPPIV (BMS) inhibitors helped advance that class of compounds. More recently the lab has been working in the electroceutical field (Boston Scientific, Galvani, and Metavention) to establish the feasibility of using nerve stimulation or blockade to alter metabolic regulation in vivo. Finally, it should be noted that Dr. Cherrington’s lab has also carried out studies focused on SGLT-2 inhibitors, 11betaHSD 1 blockers, glucagon receptor antagonists, as well as glucokinase activators. It is worth noting that his collaborations are international, such that he has worked with companies around the world including those based in the USA, Germany, France, Denmark, Japan, Switzerland and India. By offering his expertise and unique models to others he has provided important input into decision making within the pharmaceutical and bio-tech world.

Jane Chiang

Jane Chiang
Chief Medicial Officer
Diasome Pharmaceuticals
Jane Chiang
Chief Medicial Officer
Diasome Pharmaceuticals
 
About Speaker:
Joseph Cook

Joseph Cook, Jr.
President and Executive Chairman of the Board
Nusirt Inc.,
Joseph Cook, Jr.
President and Executive Chairman of the Board
Nusirt Inc.,
 
About Speaker:

Mr. Cook is a principal and co-founder of Mountain Group Capital, Nashville, TN.  Mr. Cook serves as Executive Chairman of the Board and President of NuSirt Biopharma and a board member of Castle Biosciences, Clinical Products and Corcept Therapeutics Inc. (NASDAQ: CORT).

He is also a founder and Past-Chairman of the Board of Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) a biotechnology company in Cambridge, MA where he served as a director from 1998 to 2015.  Mr. Cook served as Chairman of Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) from 1998 to 2009 and was Chief Executive Officer from 1998-2003.  Mr. Cook retired as a Group Vice-President, Global Operations at Eli Lilly and Company in 1993 after more than 28 years of service.

Mr. Cook serves as Chairman of the Board of Mercy Ministries International Inc. with headquarters in Nashville, TN.  He is also a past Chair and current member of the University of Tennessee College of Engineering Advisory Board.  Mr. Cook has served on the national board of the American Diabetes Association, and is past Chairman of the Board of Life Sciences Tennessee.

Mr. Cook graduated from the University of Tennessee in 1965 where he received his BS in Engineering with High Honors and was a UT Torchbearer.

Denise Faustman

Denise Faustman
Director of Immunobiology; Associate Professor of Medicine
Massachusetts General Hospital; Harvard Medical School
Denise Faustman
Director of Immunobiology; Associate Professor of Medicine
Massachusetts General Hospital; Harvard Medical School
 
About Speaker:

Denise Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. She currently leadd a clinical trial program investigating the potential of the BCG vaccine as a disease reversal treatment for long-standing type 1 diabetes. Her research accomplishments include the first scientific description of modifying donor tissue antigens to change their foreignness, the identification of interrupted T cell education through MHC class I, and the identification of autoimmune T cell sensitivity to TNF. For autoreactive CD8 T cell death and Treg expansion, she has identified the TNFR2 receptor and downstream signaling pathway as central.   These achievements have earned her awards including the National Institutes of Health and National Library of Medicine “Changing the Face of Medicine” Award as one of 300 American physicians (one of 35 in research) honored for seminal scientific achievements in the United States, the Oprah Achievement Award for “Top Health Breakthrough by a Female Scientist,” , election into the National Academy of Inventors, and the Women in Science Award from the American Medical Women’s Association and Wyeth Pharmaceutical Company.  Dr. Faustman’s research has been highlighted in publications including Science, Nature, The Wall Street Journal, The New York Times, Los Angeles Times, The London Financial Times and Scientific American.

 

Alexander (Zan) Fleming

Alexander (Zan) Fleming
Executive Chairman
Kinexum
Alexander (Zan) Fleming
Executive Chairman
Kinexum
 
About Speaker:

Dr. Alexander Fleming received his M.D. and internal medicine training from Emory, fellowship training in endocrinology at Vanderbilt and metabolism at National Institutes of Health, where he was a senior fellow. From 1986-98 Dr. Fleming served as reviewer and supervisory medical officer at the US Food and Drug Administration.  He acquired extensive clinical experience and regulatory responsibility in the therapeutic areas of diabetes, other metabolic and endocrine disorders, growth and development, nutrition, lipid-lowering compounds, orphan drug indications, and reproductive indications.  He led reviews of landmark approvals including those of the first statin, insulin analog, metformin, PPAR-agonist, and growth hormone for non-GH deficiency indications. He was responsible for the regulation of the earliest biotech products including human insulin and growth hormone.  He helped to shape a number of FDA policies and practices related to therapeutic review and regulatory communication.

His regulatory and technical expertise has been requested in numerous international settings including the World Health Organization, where he was assigned during 1991-92.  Dr. Fleming was a member of the expert working groups on Good Clinical Practices and General Considerations for Clinical Trials of the International Conference on Harmonization (ICH) and participated on other ICH committees including the Common Technical Document working group. 

He was also the founder and editor in chief of the Virtual Journal of Drug Evaluation, of FDA's Center for Drug Evaluation and Research (CDER), a major contributor to FDA's Good Review Practice (GRP) initiative, and chair of the committee responsible for education and training at CDER.   He conceived and led the first FDA pilot project to utilize the internet for regulatory communication. Dr. Fleming is lead author of the book, “Optimizing Development of Therapies for Diabetes.” He has frequently published scientific articles and book chapters, the most recent chapter, Regulatory Considerations for Early Clinical Development, is in Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development, published by Springer in January 2015.  He has been a member of number corporate and professional society advisory boards.  The most recent is the joint European Association for the Study of Diabetes and American Diabetes Association working group on insulin pump safety. 

Dr. Fleming founded Kinexum, a strategic advisory firm in 2003 and continues to serve as its chief executive officer.

Judith Gorski

Judith Gorski
Senior Director, CVMD and Inflammation Business Unit and Scientific Engagement
Crown Bioscience
Judith Gorski
Senior Director, CVMD and Inflammation Business Unit and Scientific Engagement
Crown Bioscience
 
About Speaker:

Dr. Judith Gorski is Global Director of Scientific Engagement at Crown Bioscience Inc., and is a pharmacologist with over 18 years of experience in drug discovery and development in a large pharmaceutical environment.  She has extensive experience in basic research and targeted drug discovery in the disease areas of type 1 and 2 diabetes, dyslipidemia, atherosclerosis, obesity, and metabolic syndrome.  Dr. Gorski has co-authored publications in Nature, Obesity, Obesity Research, Cell Metabolism, Journal of Lipid Metabolism.

Prior to joining CrownBio, Dr. Gorski’s work at Merck focused on target identification/validation and small molecule and biologics identification/optimization with the aim of recommending lead candidates for clinical development. Her primary responsibilities were to establish and validate appropriate primary, secondary and tertiary in vivo models of dyslipidemia, obesity, metabolic syndrome, and type 1 and 2 diabetes. In addition to preclinical work, Dr. Gorski has been a member of early development teams to move lead candidates into development and has collaborated across an array of disciplines, including drug safety and metabolism, pharmaceutical sciences, early clinical development, medical affairs, regulatory affairs, and commercial development.

Dr. Gorski received her Ph.D. in Neuroscience from University of Medicine and Dentistry, New Jersey.

Julia Greenstein

Julia Greenstein
Vice President, Research Strategy
JDRF
Julia Greenstein
Vice President, Research Strategy
JDRF
 
About Speaker:

Julia Greenstein is the Vice President of Research Strategy at JDRF. She has been at JDRF for over 10 years beginning in the Beta cell portfolio and serving in a variety of roles in the Cure and Prevention portfolios.

Previously she was CEO of Immerge BioTherapeutics, Inc., a Novartis Pharma/BioTransplant JV and has held the roles CSO at BioTransplant and VP of Discovery Research at ImmuLogic Pharmaceutical Corp.

She received her PhD in Microbiology from University of Rochester Medical School.  She did postdoctoral training at the University of Rochester Medical School and the Dana Farber Cancer Institute of Harvard Medical School and was an Assistant Professor the Dana Farber Cancer Institute. 

In addition, she serves on the Board of Directors of The Sage Colleges and is on the University of Rochester Regional Cabinet.

Dennis Guberski

Dennis Guberski,
President & Chairman
Biomere
Dennis Guberski,
President & Chairman
Biomere
 
About Speaker:

Dennis Guberski is a recognized expert on the development of rodent models and diabetes.  He founded Biomere as a spin-out of UMass Medical School in 1996.  His experience includes more than 20 years at the University of Massachusetts Medical School, both as a researcher and as Director of the SPF vivarium in the Department of Pathology.

A recognized expert on the development and maintenance of specialized research models including a premier system to study diabetic complications, Dennis has served as the Principal Investigator on the Type 1 Diabetes Rapid Access to Intervention Development (T1D Raid) government contract.  He has previously served as PI on numerous National Institutes of Health (NIH) contracts. Dennis was selected by NIH to participate in a taskforce to develop a National Genetic Resource Repository for laboratory rats and served as a member of the scientific review board for the NIH Autoimmune Rat Repository in Bethesda, Maryland.

Dennis received his MS in Genetics from University of Massachusetts, Amherst, MA.

Jason Hafler -panelist

Jason Hafler
Senior Director of Investments
Sanofi Ventures
Jason Hafler
Senior Director of Investments
Sanofi Ventures
 
About Speaker:

Jason joined Sanofi Ventures in 2014 with a background in early stage biotech investing and transactions. Prior to Sanofi, Jason was the Director of Corporate Development at RaNA Therapeutics, LLC a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group and a Board Observer for several portfolio companies. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space.

Jason currently serves on the Board of Directors for NeuroVia Inc., Expansion Therapeutics and is a board observer for Navitor Pharmaceuticals. In addition, he is on the Board of Directors for one additional Sanofi Ventures-backed seed stage company. In addition, he is on the Board of Trustees at the Buckingham Browne and Nichols school and on the Board of Directors of The Magdalene College Foundation.

Jason graduated with honors from Bowdoin College, and holds a Ph.D. from the University of Cambridge.

Wende Hutton

Wende Hutton
General Partner
Canaan
Wende Hutton
General Partner
Canaan
 
About Speaker:

Wende identifies, builds and invests in companies that can change the practice of medicine by bringing novel drugs, technologies and devices to market. She joined Canaan in 2004 and throughout her career she has partnered with founders to deliver more than a dozen of those innovations to patients. Her track record includes seven IPOs and six acquisitions.

Wende currently sits on the boards of Antiva Biosciences, Chrono Therapeutics, Glooko, Hyalex and OncoResponse . Her prior investments include BiPar Sciences (acquired by Sanofi-Aventis), Chimerix (CMRX), Dermira (DERM), Labrys Biologics (acquired by Teva Pharmaceutical) and Transcend Medical (acquired by Alcon/Novartis). Wende was recognized among Fierce Biotech’s 2014 "Fierce 15" women in biotech.

Wende was previously a General Partner at Mayfield. Earlier in her career, Wende held senior marketing and business development roles at GenPharm International and Nellcor. Wende spends her free time volunteering with global health and conservation organizations. She holds a B.A. in human biology from Stanford University and an M.B.A. from Harvard Business School.

 

Scott Johnson

Scott Johnson
Patient Engagement Manager, USA
mySugr GmbH
Scott Johnson
Patient Engagement Manager, USA
mySugr GmbH
 
About Speaker:

Scott is an experienced patient advocate. He works with a wide range of stakeholders across the healthcare environment to help them establish effective communication with the patient community. His expertise in the diabetes social media space is recognized worldwide and he advises organizations within the healthcare, food, and consumer goods industries.

Today he is Patient Engagment Manager, USA for mySugr and manages a long-standing and award-winning blog “Scott's Diabetes” that reaches hundreds of thousands of people annually.

Scott is also a member of the Children with Diabetes faculty where he develops educational curriculums and content for the Friends for Life annual conference and regional events. He is on the Board of Directors for the Diabetes Community Advocacy Foundation, and is a founding member of Partnering for Diabetes Change, a coalition of people living with diabetes and industry representatives working to support underserved communities. He is interested in how these types of interactions including peer-to-peer support impact patient outcomes and routinely presents his work.

Martin Lafontaine

Martin Lafontaine
Commercialization Consultant, Diabetes
Kinexum
Martin Lafontaine
Commercialization Consultant, Diabetes
Kinexum
 
About Speaker:

Martin Lafontaine has over 20 years of experience within the pharmaceutical, medical device and digital health industry, and has been a consultant since 2016. Martin has held various leadership positions in the commercial organization in both multinational (GlaxoSmithKline) and start-up organizations (Locemia Solutions), in North America and Internationally. Most recently, he has been consulting and advising several companies involved in various areas of diabetes care, through his affiliation to Kinexum, a leading regulatory, clinical, commercial and other translational resource consulting firm supporting the strategic, technical, and operational needs of small and large life science companies. Martin possesses strong expertise in commercial go-to-market product launch excellence, marketing, corporate development and business development, solidly anchored in the field of diabetes. Martin is active on the board or serves as an advisor to several diabetes-related organizations in both the for- and not-for-profit sectors, such as AYUDA, The Behavioral Diabetes Institute, and the Team Type One Foundation. Martin’s passion for diabetes has solid roots, beginning at age 13 when he was diagnosed with type 1 diabetes. He authored a chapter in the book, “Successful Men With Diabetes.”

David Maggs

David Maggs
Chief Medical Officer
Fractyl Laboratories
David Maggs
Chief Medical Officer
Fractyl Laboratories
 
About Speaker:

David is Chief Medical Officer of Fractyl.  David is a board certified endocrinologist and most recently served as Chief Medical Officer of GI Dynamics.  Previously, David spent more than a decade at Amylin Pharmaceuticals where he held positions of increasing responsibility, led numerous innovative collaborations and was directly engaged with the global diabetes and endocrine community.  David served as Amylin’s vice president, medical research and development, where he was integral to the development and commercialization of all three of the company’s marketed drugs – Symlin(R), Bydureon(R) and Byetta(R), the first amylin and GLP-1 receptor agonists respectively approved by the U.S. Food and Drug Administration for the treatment of diabetes. Prior to his Amylin tenure, David served as director, diabetes and metabolism, for Parke-Davis (now Pfizer). Previously, he held faculty appointments at the Yale School of Medicine. David initially trained at Guy’s Hospital, London, and later completed his medical and endocrine training at the University of Nottingham.

Felicia Pagliuca

Felicia Pagliuca
Vice President, Cell Biology R&D
Semma Therapeutics
Felicia Pagliuca
Vice President, Cell Biology R&D
Semma Therapeutics
 
About Speaker:

Dr. Pagliuca is scientific co-founder of Semma and currently serves as Vice President of Cell Biology R&D. She leads internal R&D efforts focused on Semma's stem cell technologies, including research/discovery, process development, manufacturing, and preclinical testing.  Dr. Pagliuca also works closely with Semma’s CEO on corporate development and overall strategy. Previously, Dr. Pagliuca was a postdoctoral fellow in Professor Doug Melton’s laboratory at the Harvard Stem Cell Institute, where she was part of the team that discovered how to generate stem cell derived beta cells and published a seminal paper in Cell - named a top ten scientific breakthrough in 2014.  She is an expert in stem cell biology and diabetes and one of the inventors of Semma Therapeutics’ key technologies.  Dr. Pagliuca received a B.S. from Duke University and a Ph.D. from Cambridge University where she was a Marshall Scholar. She was previously Director of Technology and Corporate Development at Semma, and is currently on leave from Harvard Business School where she was a Kaplan Fellow.

Steven Russell

Steven Russell
Associate Professor of Medicine
Harvard Medical School
Steven Russell
Associate Professor of Medicine
Harvard Medical School
 
About Speaker:

Dr. Russell is an Associate Professor of Medicine at Harvard Medical School and an Attending Physician at Massachusetts General Hospital Diabetes Research Center. He completed medical and doctoral (MD/PhD) training at University of Texas Southwestern Medical School and a residency in Internal Medicine and fellowship in Endocrinology at the Massachusetts General Hospital. He is board certified in Endocrinology, Diabetes & Metabolism.

Dr. Russell is the principal clinical investigator of a collaboration between Massachusetts General Hospital and Boston University to develop a wearable bionic pancreas systems for automated glycemic management in people with diabetes mellitus. Dr. Russell’s other projects include evaluation of continuous glucose monitoring technology, methods for automated management of glucose in hospitalized patients, investigations of methods to improve insulin pharmacokinetics, investigations of stable formulations of glucagon, and development of a device for minimally invasive continuous insulin monitoring.

Dr. Russell’s research has been supported by the National Institutes of Health (NIH), The Leona M. and Harry B. Helmsley Charitable Trust, the Banting Foundation, the American Diabetes Association, and the Juvenile Diabetes Research Foundation.

Aaron Schwartz

Aaron Schwartz
Director, R&D Innovation Sourcing
Novo Nordisk
Aaron Schwartz
Director, R&D Innovation Sourcing
Novo Nordisk
 
About Speaker:

Aaron is a Director in Novo Nordisk’s R&D Innovation Sourcing team.  In this capacity, Aaron is responsible for the search an evaluation of new therapeutics and enabling technologies for protein, peptide, and antibody drugs.  Prior to joining Novo Nordisk, Aaron worked in the MIT Technology Licensing Office for 13.5 years.  During this time, he worked on license and sponsored research agreements with life sciences companies from startups to big biotech/pharma and everything in between.  He also managed a portfolio of over 650 technologies.  Before Aaron’s time at MIT, he was a management consultant to big pharma and a startup.  Aaron has an undergrad degree in biology from the University of Chicago and a Masters degree in biology from MIT.

Donald Scott

Donald Scott
Professor in the Division of Endocrinology, Diabetes and Bone Disease
Icahn School of Medicine at Mount Sinai
Donald Scott
Professor in the Division of Endocrinology, Diabetes and Bone Disease
Icahn School of Medicine at Mount Sinai
 
About Speaker:

Donald K Scott is a professor of Medicine in the Diabetes Obesity and Metabolism Institute at Icahn School of Medicine at Mount Sinai in New York.  He studies nutrient regulation of gene expression, focusing on mechanisms by which metabolism activates transcriptions factors leading to altered phenotypes that impact glucose homeostasis and diabetes.  Dr. Scott received his PhD from Saint Louis University in 1992.  He trained with Dr. Daryl Granner at Vanderbilt University as a Post-Doc.  He has been a principal investigator at LSU New Orleans, University of Pittsburgh, and most recently moved Mount Sinai in New York in 2012.

 

Thomas Seoh

Thomas Seoh
Chief Executive Officer
Kinexum
Thomas Seoh
Chief Executive Officer
Kinexum
 
About Speaker:

Thomas Seoh is an entrepreneur/executive who has held senior leadership positions in public and private, pharmaceutical, biotech and medical device companies for over 25 years. After practicing corporate law in New York and London and serving as General Counsel for several companies, including Viratek in Costa Mesa, which developed the antiviral, VIRAZOLE®, and engaged in antisense oligonucleotide research, he joined Guilford Pharmaceuticals in Baltimore, which commercialized GLIADEL® wafer for glioblastoma multiforme and developed the propofol pro-drug LUSEDRA® and small molecules for Parkinson’s disease. Thomas began as Guilford's VP, General Counsel and Secretary, and later served as SVP Corporate and Commercial Development. He was then CEO of venture-backed Faust Pharmaceuticals in Strasbourg, France, developing a repurposed compound in Phase II for Parkinson’s patients, a re-positioned molecule for Duchenne muscular dystrophy and a GPCR drug discover platform. He also served on the Board of Directors of Arbios Systems, a Cedars Sinai spin-out with an ex vivo liver dialysis device in clinical development. He has additionally served as President of NexGen Medical Systems of Melbourne, Florida, commercializing a novel mechanical thrombectomy device for Deep Vein Thrombosis and stroke and a state-of-the-art neurocatheter, CEO of Eqalix, a regenerative medicine device company in Reston, VA, developing the first plant-based skin substitute wound dressing, and a member of the Hopkins Alliance, an industry-faculty advisory board at Johns Hopkins School of Medicine. Thomas holds an AB in Philosophy and History and a JD from Harvard University.

Alain Stricker-Krongrad

Alain Stricker-Krongrad
Chief Scientific Officer
Sinclair Research Center
Alain Stricker-Krongrad
Chief Scientific Officer
Sinclair Research Center
 
About Speaker:

Alain Stricker-Krongrad is Chief Scientific Officer at Sinclair Research. Alain was previously Chief Scientific Officer and Senior Scientific Adviser at Charles River Laboratories. Alain has managed pharmacokinetics, efficacy and safety departments for multiple disease indications within Charles River Laboratories, Millennium Pharmaceuticals in the U.S., and Novartis Headquarters and Ciba-Geigy in Switzerland. Alain received his License, Master and Ph.D. degrees from the University of Nancy, France. He conducted his doctoral and post-doctoral research on preclinical and clinical drug evaluation at the National Institute of Scientific and Medical Research (INSERM) for which he has received two international awards for distinguished research. Alain has received accreditations from the National List of Qualifications in both Pharmaceutical Sciences and Pharmacology (France), and is Adjunct Professor of Pharmacology at the Massachusetts College of Pharmacy. He is an elected Member of the American College of Clinical Pharmacology and a member of the American College of Toxicology. Alain has published more than 70 peer-reviewed articles and brings a wealth of expertise in preclinical and early clinical drug efficacy and safety evaluation.

Maria Trujillo

Maria Trujillo
Principal Scientist, Quantitative Pharmacology and Pharmacometrics
Merck & Co.
Maria Trujillo
Principal Scientist, Quantitative Pharmacology and Pharmacometrics
Merck & Co.
 
About Speaker:

Born in New York City. Maria received her PhD from Rutgers University studying human adipose tissue metabolism and endocrine function with Susan Fried followed by a post doc at the Diabetes Research Training Center at Albert Einstein College of Medicine in Philipp Scherer's lab. In 2006 Maria joined Merck to support projects in the Cardiometabolic Therapeutic Area as an in vivo pharmacologist. Today Maria is a Principal Scientist in the department of Quantitative Pharmacology and Phamacometrics supporting projects from drug discovery through development.

Michael Zemel

Michael Zemel
Founder and Chief Scientific Officer
Nusirt
Michael Zemel
Founder and Chief Scientific Officer
Nusirt
 
About Speaker:

Michael Zemel received his PhD in Physiology and Nutrition at the University of Wisconsin-Madison.  He then served on the faculties of Endocrinology and of Nutrition at Wayne State University and as Research Endocrinologist at the VA Medical Center associated with Wayne State from 1980 – 1990, where his work focused on endocrine regulation of cell calcium signaling and downstream effects on both blood pressure regulation and insulin sensitivity.  He moved to the University of Tennessee in 1990 where he served as Professor of Nutrition and of Medicine and expanded his work to focus on energy sensing, muscle-fat cross-talk and regulation of adipocyte metabolism.  Michael founded NuSirt in 2007 and left the university in 2012 to devote his full attention to the company, where he leads research programs focused on development of new therapeutics for obesity, diabetes and related co-morbidities.